Clinical Trials
7
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Tissue Collection Study for Patients With Non-Small Cell Lung Cancer With Resectable Disease
- Conditions
- Non-Small Cell Lung Cancer
- First Posted Date
- 2011-10-12
- Last Posted Date
- 2012-01-11
- Lead Sponsor
- Precision Therapeutics
- Target Recruit Count
- 450
- Registration Number
- NCT01450553
- Locations
- 🇺🇸
Cardio-Thoracic Surgeons, P. C., Birmingham, Alabama, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Martin Memorial Treasure Coast Surgeons, Stuart, Florida, United States
A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study
- Conditions
- Solid Organ Tumors
- First Posted Date
- 2011-01-07
- Last Posted Date
- 2012-10-05
- Lead Sponsor
- Precision Therapeutics
- Target Recruit Count
- 167
- Registration Number
- NCT01271959
- Locations
- 🇺🇸
Cardio-Thoracic Surgeons, P.C., Birmingham, Alabama, United States
🇺🇸Hematology Oncology Associates, Oakland, California, United States
🇺🇸Collaborative Research Group, Boynton Beach, Florida, United States
Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases
- Conditions
- Ovarian CancerPeritoneal CancerFallopian Tube Cancer
- First Posted Date
- 2010-01-14
- Last Posted Date
- 2011-06-03
- Lead Sponsor
- Precision Therapeutics
- Target Recruit Count
- 512
- Registration Number
- NCT01048814
- Locations
- 🇺🇸
Precision Therapeutics, Inc., Pittsburgh, Pennsylvania, United States
Retrospective Case Study Examining Patient Outcomes Compared to the ChemoFx Assay in Endometrial Cancer Patients
- Conditions
- Endometrial Cancer
- First Posted Date
- 2010-01-14
- Last Posted Date
- 2011-03-16
- Lead Sponsor
- Precision Therapeutics
- Target Recruit Count
- 76
- Registration Number
- NCT01049126
- Locations
- 🇺🇸
Precision Therapeutics, Inc., Pittsburgh, Pennsylvania, United States
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2009-11-05
- Last Posted Date
- 2012-10-05
- Lead Sponsor
- Precision Therapeutics
- Target Recruit Count
- 134
- Registration Number
- NCT01007890
- Locations
- 🇺🇸
Breastlink Medical Group, Inc, Long Beach, California, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Advanced Medical Specialties, Miami, Florida, United States
- Prev
- 1
- 2
- Next